Living Eye Drops Could Change Eye Care Forever. What the Future Holds for Microbe-Based Therapies
A new kind of eye drops could one day replace the daily ritual of squeezing a bottle over your eye every few hours. Researchers at the University of Pittsburgh School of Medicine have engineered what they call a “living eye drop,” a harmless bacterium that lives on the surface of the eye and continuously releases an anti-inflammatory protein to help injured corneas heal.
The early-stage research, published in Cell Reports in March 2026, offers a proof of concept for treating corneal injuries, dry eye disease and other ocular surface conditions without the laborious schedule of repeated daily drops. Traumatic ocular surface injuries alone affect more than 1 million Americans each year, according to the study.
How the Living Eye Drops Work
Tears constantly wash medication off the surface of the eye, which is why most ocular surface conditions require multiple drops a day, a regimen many patients struggle to keep up with. To get around that problem, the Pitt team turned to a microbe that already lives quietly under the eyelid, Corynebacterium mastitidis, a benign eye-dwelling bacterium. The researchers genetically modified it to continuously secrete interleukin-10 (IL-10), a small protein that regulates inflammation, so the treatment essentially sets up shop and keeps working on its own.
“This is the first demonstration that a microbe that lives on the ocular surface could be engineered to deliver a therapeutic that improves eye health,” said senior author Anthony St. Leger, associate professor of ophthalmology and of immunology and a faculty member of the UPMC Vision Institute. “It opens the door to the idea of ‘living medicine’ for the eye, something you apply once, and it stays, protects and helps the tissue heal.”
What the Research Showed About Cornea Healing
In experiments with mice, corneas that were gently scratched and then treated with the engineered bacteria healed faster than those treated with unmodified bacteria or saline. When researchers blocked the IL-10 receptor, the benefit disappeared, confirming the healing effect was specifically tied to the protein the engineered microbe was producing. The team also created a version of the bacterium that releases human IL-10, which improved wound closure in lab-grown cells from the outermost layer of human cornea and reduced inflammatory signaling in human immune cells.
According to the study summary, “Engineered microbes stably colonize the eye and release mouse (mIL-10) or human IL-10 (hIL-10) that modulates local immunity and accelerates wound repair after an initial inoculation event.” The researchers describe the modified bacterium as a “live biotherapeutic product,” or LBP, a category of therapy that has shown promise in pre-clinical and clinical trials for conditions like Crohn’s disease and irritable bowel syndrome.
Why a Living Treatment Could Change Ocular Care
What makes this approach different from existing eye drops is that the therapy is built to stick around. Standard drops have to be reapplied constantly because tears wash them away, and conditions like corneal abrasions or dry eye disease often go undertreated as a result. A microbe that colonizes the eye and produces medication on its own could, in theory, eliminate that compliance problem and lower production costs, since the therapeutic comes from the bacterium itself rather than a synthetic manufacturing process.
The system is also designed to be flexible. “What makes this exciting is that the system is modular,” St. Leger explained. “We built it so you can swap in different genes, different cytokines, growth factors or other proteins, to tailor the therapy to specific eye diseases.”
Limits of the Research and What Comes Next
This is a proof of concept, not a finished treatment. The work has only been tested in mice and in lab-grown human cells, and the researchers are clear that significant development is still ahead before anything like this could reach a clinical trial. One open question is how to switch off the protein production once a patient no longer needs it.
“More research is certainly needed, particularly to determine how to deactivate the protein once treatment is no longer necessary,” St. Leger said, per UPMC. “But the findings in this study are promising, and could open the door to the development of ‘living’ medications for a range of vision conditions.”
He also described the experience of seeing the engineered microbe actually work. “In my lab, we don’t typically build tools from the ground up,” St. Leger said. “Seeing a measurable improvement in healing in an animal model using something we engineered was incredibly rewarding, and it points us toward intriguing possibilities for future research.”
What This Could Mean for Patients With Eye Conditions
Although the engineered C. mastitidis has not been evaluated in humans, the approach could eventually lead to more durable treatments for corneal injuries, severe dry eye disease and other inflammatory disorders of the ocular surface. Together, those conditions affect millions of Americans each year and typically require frequent medicated drops to manage symptoms.
The researchers say refining the technology to deliver other proteins or naturally derived factors could expand its usefulness to additional eye diseases. For now, the work establishes that engineered live biotherapeutics are a serious avenue for delivering sustained anti-inflammatory and regenerative treatment directly to the eye, a meaningful step toward a future where a single dose of a living eye drop could replace weeks of bottle-squeezing.
This article was created by content specialists using various tools, including AI.
This story was originally published June 15, 2026 at 10:00 PM with the headline "Living Eye Drops Could Change Eye Care Forever. What the Future Holds for Microbe-Based Therapies."
